RESUMEN

OBJECTIVE: The aim of this study was to ensure patients' safety and to enhance treatment efficacy, knowledge about pharmacokinetic interactions even in complex clinical situations of polypharmacy is invaluable. This study is to uncover the potential of pharmacokinetic interactions between venlafaxine and trimipramine in a naturalistic sample. METHODS: Out of a therapeutic drug monitoring database with plasma concentrations of venlafaxine (VEN) and O-desmethylvenlafaxine (ODV), we considered two groups of patients receiving venlafaxine without known cytochrome P450 confounding medications, taking solely venlafaxine: V0 (n = 905), and a group of patients co-medicated with trimipramine, VTRIM (n = 33). For VEN, ODV and active moiety (sum of VEN + ODV) plasma concentrations and dose-adjusted concentrations as well as ODV/VEN ratios were compared between groups using the Mann-Whitney U test with a significance level of 0.05. RESULTS: Patients co-medicated with trimipramine had higher plasma concentrations of VEN (183.0 vs. 72.0, +154%, P = 0.002) and AM (324.0 vs. 267.5, +21%, P = 0.005) and higher dose adjusted plasma concentrations than patients in the control group (P = 0.001 and P = 0.003). No differences were found for ODV and C/D ODV (P < 0.05 for both comparisons). The metabolite to parent ratio, ODV/VEN, was significantly lower in the VTRIM group (1.15 vs. 2.37, P = 0.012). CONCLUSION: Findings suggest inhibitory effects of trimipramine on venlafaxine pharmacokinetics most likely via an inhibition of CYP 2D6 or by saturated enzyme capacity. The lack of in vitro data hampers the understanding of the exact mechanisms. Clinicians should be aware of drug-drug interactions when combining these agents. Therapeutic drug monitoring helps to ensure treatment efficacy and patients' safety.

Asunto(s)

Succinato de Desvenlafaxina/sangre , Trimipramina/farmacología , Clorhidrato de Venlafaxina/sangre , Adulto , Succinato de Desvenlafaxina/farmacocinética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trimipramina/sangre , Clorhidrato de Venlafaxina/farmacocinética

RESUMEN

A novel carbon nanocomposite paste electrode was prepared and used as a voltammetric sensor for ultratrace determination of trimipramine (TRI) which currently used for the treatment of psychiatric disorders. For this aim, nanoparticles of molecularly imprinted polymer (MIP), synthesized by precipitation polymerization method, and multi-walled carbon nanotubes (MWCNTs) were embedded in a nanocomposite paste electrode. The nanocomposite mixing style demonstrated a significant influence on the final electrode performance. The sensor exhibited linear response range of 1.0 × 10-10-2.5 × 10-8 mol L-1 and very high sensitivity of 2131 µA µâ€¯mol L-1. The lower detection limit of the sensor was calculated to be 4.5 × 10-11 mol L-1 (S/N = 3). This sensor was applied successfully for highly selective determination of TRI in pharmaceutical formulations, urine and serum samples without applying any sample pretreatment.

Asunto(s)

Antidepresivos Tricíclicos/sangre , Antidepresivos Tricíclicos/orina , Técnicas Biosensibles/métodos , Impresión Molecular/métodos , Polímeros/química , Trimipramina/sangre , Trimipramina/orina , Antidepresivos Tricíclicos/análisis , Técnicas Biosensibles/instrumentación , Técnicas Electroquímicas/instrumentación , Técnicas Electroquímicas/métodos , Electrodos , Humanos , Límite de Detección , Nanoestructuras/química , Nanoestructuras/ultraestructura , Nanotubos de Carbono/química , Nanotubos de Carbono/ultraestructura , Polimerizacion , Comprimidos , Trimipramina/análisis

RESUMEN

An Amberlite XAD-2 (XAD2) and titanium dioxide nanoparticles (TNPs) modified glassy carbon paste electrode (XAD2-TNP-GCPE) was developed for the determination of imipramine (IMI), trimipramine (TRI) and desipramine (DES). The electrochemical behavior of these molecules was investigated employing cyclic voltammetry (CV), chronocoulometry (CC), electrochemical impedance spectroscopy (EIS) and adsorptive stripping differential pulse voltammetry (AdSDPV). After optimization of analytical conditions using a XAD2-TNP-GCPE electrode at pH 6.0 phosphate buffer (0.1 M), the peak currents were found to vary linearly with its concentration in the range of 1.30 × 10(-9) to 6.23 × 10(-6) M for IMI, 1.16 × 10(-9) to 6.87 × 10(-6) M for TRI and 1.43 × 10(-9) to 5.68 × 10(-6) M for DES. The detection limits (S/N = 3) of 3.93 × 10(-10), 3.51 × 10(-10) and 4.35 × 10(-10) M were obtained for IMI, TRI and DES respectively using AdSDPV. The prepared modified electrode showed several advantages such as a simple preparation method, high sensitivity, very low detection limits and excellent reproducibility. The proposed method was employed for the determination of IMI, TRI and DES in pharmaceutical formulations, blood serum and urine samples.

Asunto(s)

Antidepresivos Tricíclicos/análisis , Desipramina/análisis , Técnicas Electroquímicas/métodos , Imipramina/análisis , Trimipramina/análisis , Adsorción , Antidepresivos Tricíclicos/sangre , Antidepresivos Tricíclicos/orina , Carbono/química , Desipramina/sangre , Desipramina/orina , Electrodos , Humanos , Imipramina/sangre , Imipramina/orina , Límite de Detección , Nanopartículas/química , Preparaciones Farmacéuticas/química , Reproducibilidad de los Resultados , Resinas Sintéticas/química , Titanio/química , Trimipramina/sangre , Trimipramina/orina

RESUMEN

A sensitive, simple and reproducible method was developed for preconcentration and determination of trimipramine (TPM) enantiomers in biological samples using electromembrane extraction combined with cyclodextrin-modified capillary electrophoresis (CE). During the extraction, TPM enantiomers migrated from a 5 mL sample solution through a thin layer of 2-nitrophenyl octyl ether NPOE immobilized in the pores of a hollow fiber, and into a 20 µL acidic aqueous acceptor phase presented inside the lumen of the fiber. A Box-Behnken design and the response surface methodology (RSM) were used for the optimization of different variables on extraction efficiency. Optimized extraction conditions were: NPOE as supported liquid membrane, inter-electrode distance of 5 mm, stirring rate of 1000 rpm, 51 V potential difference, 34 min as the extraction time, acceptor phase pH 1.0 and donor phase pH 4.5. Then, the extract was analyzed using optimized cyclodextrin (CD)-modified CE method for the separation of TPM enantiomers. Best results were achieved using 100 mM phosphate running buffer (pH 2.0) containing 10 mM α-CD as the chiral selector, applied voltage of 18 kV and 20°C. The range of quantitation for both enantiomers was 20-500 ng/mL. The method was very reproducible so that intra- and interday RSDs (n=6) were <6%. The limits of quantitation and detection for both enantiomers were 20 and 7 ng/mL, respectively. Finally, this method was successfully applied to determine the concentration of TPM enantiomers in plasma and urine samples without any pre-treatment.

Asunto(s)

Ciclodextrinas/química , Electroforesis Capilar/métodos , Extracción Líquido-Líquido/métodos , Trimipramina/análisis , Trimipramina/química , Análisis de Varianza , Humanos , Límite de Detección , Membranas Artificiales , Reproducibilidad de los Resultados , Cloruro de Sodio , Estereoisomerismo , Trimipramina/sangre , Trimipramina/orina

RESUMEN

A novel method based on three-phase hollow fiber microextraction technique (HF-LPME) coupled with electrospray ionization-ion mobility spectrometry (ESI-IMS) was developed for the simultaneous determination of two antidepressant drugs (trimipramine and desipramine) in urine and plasma samples. The effects of various parameters such as type of organic solvent, composition of donor and acceptor phase, stirring rate, salt addition, extraction time, and temperature were investigated. Under the optimized conditions, the relative standard deviation was in the range of 5-6%, and the method quantitation limit (MQL) of utilizing HF-LPME/ESI-IMS was 5 µg/L for both drugs. The relative recoveries obtained by the proposed method from urine and plasma samples were in the range 94% to 97% for trimipramine and 92% to 96% for desipramine. Finally, the feasibility of the proposed method was successfully confirmed by extraction and determination of trace amounts of trimipramine and desipramine in biological samples without any significant matrix effect.

Asunto(s)

Antidepresivos/sangre , Antidepresivos/orina , Desipramina/sangre , Desipramina/orina , Microextracción en Fase Sólida/métodos , Espectrometría de Masa por Ionización de Electrospray/métodos , Trimipramina/sangre , Trimipramina/orina , Antidepresivos/aislamiento & purificación , Desipramina/aislamiento & purificación , Humanos , Microextracción en Fase Sólida/instrumentación , Trimipramina/aislamiento & purificación

RESUMEN

Singular coronary arteries are a rare feature appearing in approximately 0.05% of the population. The clinical relevance of those anomalies varies a lot. The wide range of descriptions reaches from asymptomatic cases to sudden cardiac death. This will be discussed in a case report concerning a 31-year-old woman who was found dead in her apartment. Due to drugs that were found next to her, a suicide was assumed. The autopsy yielded an aplastic right coronary artery and a left coronary artery with an anomalous origin of the circumflex branch as well as a myocardial scar. The autopsy findings and the results of the toxicological examinations are presented and discussed in view of the cause of death.

Asunto(s)

Anomalías de los Vasos Coronarios/patología , Adulto , Analgésicos Opioides/sangre , Antidepresivos Tricíclicos/sangre , Depresores del Sistema Nervioso Central/orina , Femenino , Patologia Forense , Humanos , Miocardio/patología , Piretrinas/orina , Tilidina/análogos & derivados , Tilidina/sangre , Trimipramina/sangre

RESUMEN

OBJECTIVE: The tricyclic antidepressant trimipramine is one of the drugs with the most pronounced differences in pharmacokinetics caused by the CYP2D6 genetic polymorphism. However, the effect of CYP2D6 genotype on steady state kinetics and on bioavailability has not been studied so far. In addition, we were interested in trimipramine pharmacokinetics in genetically defined ultra rapid metabolizers. METHODS: We studied intravenous and multiple dose oral application of 50 mg trimipramine in five, seven, and three healthy volunteers with CYP2D6 genotypes predicting deficient, highly active and ultrarapid metabolism. The latter group included carriers of one wild-type and one duplication allele. Trimipramine and desmethyltrimipramine concentrations were measured by HPLC over a time interval of 72 h after intravenous and after one oral application. RESULTS: Both bioavailability and systemic clearance significantly depended on CYP2D6 genotype with a linear gene dose relationship. Mean bioavailability was 44, 16 and 12% in carriers of zero, two and three active genes of CYP2D6, respectively, and the corresponding data for systemic clearance were 12.0, 24.2, and 30.3 l/h. Consequently, the mean total oral clearances were 27.3, 151, and 253 l/h in poor, extensive and ultrarapid metabolizers. CONCLUSIONS: High bioavailability combined with low systemic clearance of trimipramine in poor metabolizers of CYP2D6 substrates results in a very high exposure to trimipramine with the risk of adverse drug reactions. On the other hand, the extremely high systemic and presystemic elimination may result in sub-therapeutic drug concentrations in carriers of CYP2D6 gene duplications with a high risk of poor therapeutic response.

Asunto(s)

Antidepresivos Tricíclicos/farmacocinética , Citocromo P-450 CYP2D6/genética , Trimipramina/análogos & derivados , Trimipramina/farmacocinética , Administración Oral , Antidepresivos Tricíclicos/administración & dosificación , Antidepresivos Tricíclicos/sangre , Cromatografía Líquida de Alta Presión , Genotipo , Humanos , Infusiones Intravenosas , Trimipramina/administración & dosificación , Trimipramina/sangre

RESUMEN

The treatment of delusional depression is a major challenge in psychopharmacology. Hypothalamic-pituitary-adrenocortical (HPA) overdrive may contribute, via increased dopaminergic activity, to the pathophysiology of the disorder. Trimipramine appears to be an interesting potential candidate, since it is an atypical antidepressant that is known to inhibit HPA activity. In a four-week open trial we investigated its effects in 15 inpatients with delusional depression. The dosage was increased within 7 days up to 300 - 400 mg/d and was then maintained for three weeks. Psychometric assessments and safety monitoring were conducted weekly. Assessment of the HPA activity was achieved by a combined dexamethasone suppression/corticotropin-releasing hormone stimulation (Dex/CRH) test before and after four weeks of treatment. Therapeutic response was defined as a decrease in the HAMD-score of at least 50 %. Eight out of 13 completers were rated as responders. Therapeutic response was associated with L, D-trimipramine concentrations higher than 160 ng/ml. Intent-to-treat analysis showed significant improvement in psychometric variables. Despite the high dosage, the substance was generally well tolerated, with the exception of one patient who suffered from a hypotensive reaction. Mean +/- SD concentration of L-trimipramine and D-trimipramine were 138 +/- 61 ng/ml and 119 +/- 50 ng/ml at a final dose of 346 +/- 50 mg/d. The ACTH and cortisol area under the curve in the Dex/CRH tests decreased significantly, reflecting a decrease of activity in the HPA system. We suggest that the clinical use of high-dose trimipramine in delusional depression seems to be a promising treatment strategy.

Asunto(s)

Antidepresivos Tricíclicos/administración & dosificación , Trastorno Depresivo Mayor/tratamiento farmacológico , Esquizofrenia Paranoide/tratamiento farmacológico , Trimipramina/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Antidepresivos Tricíclicos/efectos adversos , Antidepresivos Tricíclicos/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Psicometría , Resultado del Tratamiento , Trimipramina/efectos adversos , Trimipramina/sangre

RESUMEN

The phenomenon of a heterogeneous response to the same drug in different patients is well-known. An important reason is that, even at equal concentrations, the bioavailability of a drug depends on the interaction of the drug with the blood-brain barrier (BBB). In part, this is due to the drug-transporting P-glycoprotein (P-gp), a product of the multiple drug resistance gene (ABCB1), which can transport drugs against a concentration gradient across the BBB back into the plasma and thereby reduce the bioavailability in the brain. In the present study, we have examined the uptake of the antidepressants citalopram and trimipramine into the brain of abcb1ab knockout mice compared with controls. One hour after s.c. injection of the drugs, concentrations of the two drugs and of the metabolite d-trimipramine in brain, spleen, kidney, liver and plasma were measured with HPLC. Significantly higher brain concentrations in knockout mice, showing that these drugs are substrates of P-gp and that the presence of P-gp reduces the effective bioavailability of these substances in the brain. The results of our study contradict an earlier report that citalopram is not actively transported from endothelial cells. These results were derived from an in vitro study, showing that due to the complexity of the BBB-drug interaction, it is difficult to transfer results from in vitro studies to the in vivo situation. We hypothesize that inter-individual differences in the activity of the ABCB1 gene can account in part for the great variation in clinical response to antidepressants in psychiatric patients, even at comparable plasma levels.

Asunto(s)

Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antidepresivos Tricíclicos/farmacocinética , Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/metabolismo , Citalopram/farmacocinética , Genes MDR/genética , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Trimipramina/farmacocinética , Animales , Antidepresivos Tricíclicos/sangre , Antidepresivos Tricíclicos/química , Disponibilidad Biológica , Técnicas de Cultivo de Célula , Cromatografía Líquida de Alta Presión , Citalopram/sangre , Citalopram/química , Femenino , Expresión Génica/genética , Homocigoto , Riñón/metabolismo , Hígado/metabolismo , Masculino , Ratones , Ratones Noqueados , Inhibidores Selectivos de la Recaptación de Serotonina/sangre , Inhibidores Selectivos de la Recaptación de Serotonina/química , Bazo/metabolismo , Trimipramina/sangre , Trimipramina/química

RESUMEN

Steady state plasma concentrations of the (L)- and (D)-enantiomers of trimipramine (TRI), desmethyltrimipramine (DTRI), 2-hydroxytrimipramine (TRIOH) and 2-hydroxydesmethyl-trimipramine (DTRIOH) were measured in 27 patients receiving between 300 and 400 mg/day racemic TRI. The patients were phenotyped with dextromethorphan and mephenytoin, and the 8-hour urinary ratios of dextromethorphan/dextrorphan, dextromethorphan/3-methoxymorphinan, and (S)-mephenytoin/(R)mephenytoin were used as markers of cytochrome P-450IID6 (CYP2D6), CYP3A4/5 and CYP2C19 activities, respectively. One patient was a CYP2D6 and one was a CYP2C19 poor metabolizer. A stereoselectivity in the metabolism of TRI has been found, with a preferential N-demethylation of (D)-TRI and a preferential hydroxylation of (L)-TRI. CYP2D6 appears to be involved in the 2-hydroxylation of (L)-TRI, (L)DTRI and (D)-DTRI, but not of (D)-TRI, as significant correlations were measured between the dextromethorphan/dextrorphan ratios and the (L)-TRI/(L)-TRIOH (r = 0.45, p = 0.019), the (L)-DTRI/(L)-DTRIOH (r = 0.47, p = 0.014), and the (D)-DTRI/(D)-DTRIOH (r = 0.51, p = 0.006), but not with the (D)-TRI/(D)-TRIOH ratios (r = 0.29, NS). CYP2C19, but not CYP2D6, appears to be involved in the demethylation pathway, with a stereoselectivity toward the (D)-enantiomer of TRI, as a significant positive correlation was calculated between the mephenytoin (S)/(R) ratios and the concentrations to dose-to-weight ratios of (D)-TRI (r = 0.69, p = 0.00006). CYP3A4/5 appears to be involved in the metabolism of (L)-TRI to a presently not determined metabolite. The CYP2D6 poor metabolizer had the highest (L)-DTRI and (D)-DTRI concentrations to dose-to-weight ratios, and the CYP2C19 poor metabolizer had the highest (L)-TRI and (D)-TRI concentrations to dose-to-weight ratios of the group.

Asunto(s)

Antidepresivos Tricíclicos/sangre , Hidrocarburo de Aril Hidroxilasas , Citocromo P-450 CYP2D6/fisiología , Sistema Enzimático del Citocromo P-450/fisiología , Oxigenasas de Función Mixta/fisiología , Trimipramina/sangre , Adulto , Anciano , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP3A , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenotipo , Estereoisomerismo , Trimipramina/metabolismo

RESUMEN

A 53-year-old woman who was diagnosed as suffering from depression was found dead in her bed. The autopsy revealed no morphological changes sufficient to explain death. Toxicological analysis was performed and the drugs trimipramine (2.33 mg/l), citalopram (4.81 mg/l) and zolpidem (0.07 mg/l) were identified in the femoral blood. A combined drug intoxication resulting in synergistic effects to cardiovascular disorders was proposed as the cause of death. An acute overdose and suicide was suggested by calculation of the parent drug to main metabolite ratios in femoral blood and liver tissue. The trimipramine to desmethyltrimipramine ratios were calculated to be 2.06 and 3.18, the citalopram to desmethylcitalopram ratios were 1.96 and 2.02.

Asunto(s)

Antidepresivos de Segunda Generación/envenenamiento , Antidepresivos Tricíclicos/envenenamiento , Citalopram/envenenamiento , Trimipramina/envenenamiento , Antidepresivos de Segunda Generación/sangre , Antidepresivos Tricíclicos/sangre , Citalopram/análogos & derivados , Citalopram/sangre , Depresión/tratamiento farmacológico , Sobredosis de Droga , Sinergismo Farmacológico , Resultado Fatal , Femenino , Humanos , Hipnóticos y Sedantes/sangre , Hipnóticos y Sedantes/envenenamiento , Hígado/química , Persona de Mediana Edad , Piridinas/sangre , Piridinas/envenenamiento , Suicidio , Trimipramina/análogos & derivados , Trimipramina/sangre , Zolpidem

RESUMEN

A sensitive and stereospecific method for the quantitation of trimipramine enantiomers in human serum was developed. The assay involves the use of a novel mixed-mode disc solid-phase extraction for serum sample clean-up prior to HPLC analysis and is also free of interference from the enantiomers of desmethyltrimipramine, 2-hydroxytrimipramine, and 2-hydroxydesmethyltrimipramine, the three major metabolites of trimipramine. Chromatographic resolution of trimipramine enantiomers was performed on a reversed-phase cellulose-based chiral column (Chiralcel OD-R) under isocratic conditions using a mobile phase consisting of 0.3 M aqueous sodium perchlorate-acetonitrile (58:42, v/v) at a flow-rate of 0.5 ml/min. Recoveries for R- and S-trimipramine enantiomers were in the range of 93-96% at 25-185 ng/ml levels. Intra-day and inter-day precisions calculated as R.S.D. were in the ranges of 0.30-8.00% and 1.60-10.20% for both enantiomers, respectively. Intra-day and inter-day accuracies calculated as percent error were in the 0.01-2.10% and 1.00-3.00% ranges for both enantiomers, respectively. Linear calibration curves were in the concentration range 15-250 ng/ml for each enantiomer in serum. The limit of quantification of each enantiomer was 15 ng/ml. The detection limit for each enantiomer in serum using a UV detector set at 210 nm was 10 ng/ml (S/N=2). In addition, separation of the enantiomers of desmethyltrimipramine, 2-hydroxytrimipramine, and 2-hydroxydesmethyltrimipramine were investigated. The desmethyltrimipramine enantiomers could be resolved on the Chiralcel OD-R column under the same chromatographic conditions as the trimipramine enantiomers, but the other two metabolite enantiomers required different mobile phases on the Chiralcel OD-R column to achieve satisfactory resolution with Rs values of 1.00.

Asunto(s)

Antidepresivos Tricíclicos/sangre , Trimipramina/sangre , Cromatografía Líquida de Alta Presión/métodos , Humanos , Espectrofotometría Ultravioleta , Estereoisomerismo , Trimipramina/análogos & derivados

RESUMEN

A simple method for the extraction of four tricyclic antidepressants from whole blood by headspace solid-phase microextraction (SPME) is presented. The whole blood samples contain four drugs (amitriptyline, chlorimipramine, imipramine, and trimipramine) and are heated at 100 degrees C in a septum-capped vial in the presence of distilled water and NaOH solution; a polydimethylsiloxane-coated SPME fiber is exposed to the headspace of the vial to allow adsorption of the drugs before capillary gas chromatography (GC) with flame-ionization detection. The headspace SPME-GC produces intense peaks for each drug with very little background noise. Recoveries of the four drugs by the present method are 5.3-12.9%. The calibration curves for the drugs show linearity in the range of 31-1000 ng/0.5 mL. The detection limits of each drug are 16-25 ng/0.5 mL. Imipramine is detectable from rat blood 5 h after oral administration of imipramine (500 mg/kg body weight); the concentration is 1.44 +/- 0.209 micrograms/mL.

Asunto(s)

Amitriptilina/sangre , Antidepresivos Tricíclicos/sangre , Cromatografía de Gases/métodos , Clomipramina/sangre , Imipramina/sangre , Trimipramina/sangre , Animales , Humanos , Masculino , Ratas , Ratas Wistar , Hidróxido de Sodio/química , Agua/química

RESUMEN

In an open pilot study of 21 therapy-resistant depressive inpatients, plasma levels of antidepressants were determined during treatment with a combination of moclobemide/ trimipramine (n = 15) and moclobemide/maprotiline (n = 6). After combined administration of trimipramine and moclobemide (MCB), a significant increase in the plasma level of trimipramine (39%) was observed. After combination of maprotiline with moclobemide, maprotiline levels were increased (25%, n.s.). The results show that moclobemide, as an inhibitor of isoenzymes of the cytochrome P 450 oxidase, can cause increases in the plasma levels of tricyclic and tetracyclic antidepressants. No correlation between the serum level of the antidepressants and treatment outcome was found in this open study.

Asunto(s)

Antidepresivos/administración & dosificación , Antidepresivos/sangre , Benzamidas/administración & dosificación , Trastorno Depresivo/sangre , Maprotilina/sangre , Inhibidores de la Monoaminooxidasa/administración & dosificación , Trimipramina/sangre , Adulto , Anciano , Trastorno Depresivo/tratamiento farmacológico , Interacciones Farmacológicas , Resistencia a Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Masculino , Maprotilina/administración & dosificación , Persona de Mediana Edad , Moclobemida , Trimipramina/administración & dosificación

RESUMEN

A capillary gas chromatographic method with mass-selective detection was developed for the determination of oxeladin in human plasma. Plasma samples (1 mL) were alkalinized and extracted using 5mL of hexane: isoamyl alcohol (99:1). The method was demonstrated to be sensitive (limit of quantitation at 1 ng/mL), linear between 1 and 150 mg/mL, accurate and precise enough (mean error and mean coefficient of variation at the limit of quantitation were 2.3 and 13.3%, respectively) to support pharmacokinetic evaluation of the drug at doses down to 30 mg.

Asunto(s)

Antitusígenos/sangre , Fenilbutiratos/sangre , Cromatografía de Gases y Espectrometría de Masas , Humanos , Trimipramina/sangre

RESUMEN

A depressive patient, a non-responder to trimipramine (TRI), was comedicated first with citalopram (CIT) and then with fluvoxamine (FLUV). Both the TRI-CIT and TRI-FLUV combination treatments led to a worsening of the depressive state and to the appearance of panic attacks. The addition of FLUV to TRI resulted in a twofold increase of the plasma levels of TRI and to a slight increase of its N-demethylated and 2-hydroxylated metabolites. These results suggest that the interaction between FLUV and TRI occurred at the level of cytochrome P-450IID6 and cytochrome P-450meph in this patient, phenotyped as an extensive metabolizer of both dextromethorphan and mephenytoin. The adverse effects were possibly due to (a) a pharmacokinetic interaction between CIT and FLUV with TRI and/or (b) alterations in serotonergic and/or dopaminergic neurotransmission.

Asunto(s)

Trastorno Depresivo/sangre , Fluvoxamina/efectos adversos , Trimipramina/sangre , Anciano , Citalopram/efectos adversos , Citalopram/uso terapéutico , Trastorno Depresivo/complicaciones , Trastorno Depresivo/tratamiento farmacológico , Dextrometorfano/farmacocinética , Interacciones Farmacológicas , Femenino , Fluvoxamina/uso terapéutico , Humanos , Mefenitoína/farmacocinética , Fenotipo , Trimipramina/efectos adversos , Trimipramina/uso terapéutico

RESUMEN

A gas chromatographic-mass spectrometric (GC-MS) method has been developed, for the determination of trimipramine (TRI), desmethyltrimipramine (DTRI), didesmethyltrimipramine (DDTRI), 2-hydroxytrimipramine (2-OH-TRI) and 2-hydroxydesmethyltrimipramine (2-OH-DTRI). The method includes two derivatization steps with trifluoroacetic acid anhydride and N-methyl-N-(tert.-butyldimethyl silyl)trifluoroacetamide and the use of an SE-54 capillary silica column. The limits of quantitation were found to be 2 ng/ml for DTRI and 4 ng/ml for all other substances. Besides, methods have been optimized for the hydrolysis of the glucuronic acid conjugated metabolites. This specific detection method is useful, as polymedication is a usual practice in clinical situations, and its sensitivity allows its use for single-dose pharmacokinetic studies.

Asunto(s)

Trimipramina/sangre , Biotransformación , Cromatografía Líquida de Alta Presión , Remoción de Radical Alquila , Cromatografía de Gases y Espectrometría de Masas , Glucuronatos/metabolismo , Humanos , Hidroxilación , Trimipramina/farmacocinética

RESUMEN

The lot-to-lot reproducibilities of Bond Elut Certify and Clean Screen DAU columns are described. The recoveries of five test drugs obtained from twelve lots of Bond Elut Certify columns ranged from 84 to 104% with standard deviations of less than 9%. The recoveries of five test drugs obtained from six lots of Clean Screen DAU columns ranged from 81 to 103% with standard deviations of less than 7%. The 95% confidence intervals of the means as obtained by ANOVA demonstrate that there are no significant differences between the tested lots of Bond Elut Certify and Clean Screen DAU columns. Comparison of the two brands shows that both Bond Elut Certify and Clean Screen DAU columns are well acceptable for routine drug screening in systematic toxicological analysis, with a slightly higher overall recovery for the former.

Asunto(s)

Cromatografía Liquida/instrumentación , Preparaciones Farmacéuticas/análisis , Animales , Bovinos , Cromatografía Liquida/métodos , Hexobarbital/sangre , Mepivacaína/sangre , Metanfetamina/sangre , Pentobarbital/sangre , Prazepam/sangre , Reproducibilidad de los Resultados , Trimipramina/sangre

RESUMEN

A simple procedure is described that permits the simultaneous determination of trimipramine and its two major metabolites, desmethyl- and hydroxytrimipramine, in human plasma or red blood cells (RBCs) at therapeutic concentrations. The extracted biological fluids are injected into a capillary gas chromatograph with an OV-1 fused-silica column coupled to a nitrogen-phosphorus-selective detector. The limit of determination for trimipramine is 3 ng/ml and for that desmethyl- and hydroxytrimipramine is 4 ng/ml. The method permits the RBC/plasma ratios to be determined and to be correlated with the clinical response.

Asunto(s)

Cromatografía de Gases/métodos , Eritrocitos/química , Trimipramina/sangre , Humanos , Nitrógeno/química , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Trimipramina/análogos & derivados

RESUMEN

This paper describes a reversed-phase high-performance liquid chromatographic method which will simultaneously measure dothiepin and its three major metabolites (northiaden, northiaden-S-oxide and dothiepin-S-oxide) in plasma using trimipramine as internal standard. Sample preparation involved a basic extraction using diethyl ether followed by an acid back-extraction. The method we report is linear over the range 50-1000 ng/ml (r = 0.999), for all analytes. Total imprecision is less than 11% (coefficient of variation) and accuracy is greater than 94% (n = 20). Recovery of analytes varied considerably from 51.7% for northiaden-S-oxide to 90.2% for dothiepin-S-oxide.

Asunto(s)

Cromatografía Líquida de Alta Presión/métodos , Dotiepina/sangre , Humanos , Estándares de Referencia , Reproducibilidad de los Resultados , Trimipramina/sangre